# Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

Study · id `cardio:ct-nct01984424` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01984424](<https://clinicaltrials.gov/study/NCT01984424>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01984424

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 511 participants.

## Technical summary

Registry record NCT01984424. Randomized; quadruple masking; primary purpose treatment. Start 2013-12-10 (actual); primary completion 2015-11-10 (actual). Results posted on 2018-03-13.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 511 participants (enrolled count; ClinicalTrials.gov record NCT01984424, source copy `cardio:ctgov-nct01984424-2018-11-29`, retrieved 2026-10-31)
- Started: 2013-12-10 (actual) (ClinicalTrials.gov record NCT01984424, source copy `cardio:ctgov-nct01984424-2018-11-29`, retrieved 2026-10-31)
- Primary completion: 2015-11-10 (actual) (ClinicalTrials.gov record NCT01984424, source copy `cardio:ctgov-nct01984424-2018-11-29`, retrieved 2026-10-31)
- Completion: 2017-11-21 (actual) (ClinicalTrials.gov record NCT01984424, source copy `cardio:ctgov-nct01984424-2018-11-29`, retrieved 2026-10-31)
- Results first posted: 2018-03-13 (ClinicalTrials.gov record NCT01984424, source copy `cardio:ctgov-nct01984424-2018-11-29`, retrieved 2026-10-31)
- Countries: United States; Australia; Canada; Czechia; Denmark; France; Germany; Italy; Netherlands; New Zealand; Norway; South Africa; United Kingdom (ClinicalTrials.gov record NCT01984424, source copy `cardio:ctgov-nct01984424-2018-11-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01984424-2018-11-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
- Acronym: GAUSS-3
- Condition: Hyperlipidemia
- Intervention (Drug): Atorvastatin
- Intervention (Drug): Placebo to Atorvastatin
- Intervention (Other): Placebo to Ezetimibe
- Intervention (Drug): Ezetimibe
- Intervention (Other): Placebo to Evolocumab
- Intervention (Drug): Evolocumab
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention name matches this record: Ezetimibe (`cardio:ezetimibe`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial (`cardio:pubmed-27039291`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 371377ec3614db85174a4d9797439a6f6d6711c0754fbfad028239addc81f57c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
